Unending debate: statin dilemma in the management of heart failure.

摘要

In their recently published article Erbs et al. aimed to evaluate the pleiotropic effects of rosuvastatin on vascular and tissue regeneration, its impact on endothelial function and hemodynamics in 42 patients with chronic heart failure (CHF) [1]. They found that rosuvastatin activates circulating progenitor cells (CPCs) that contribute to neovascularisation and to the enhancement of endothelial function in CHF. Also they demonstrated that rosuvastatin improved LV performance by partly correction of vascular abnormalities.Early evidenceof the role of statins in patients with systolic heart failure (HF) came from observational studies and post hoc subgroup analyses in statin trials for coronary disease which tended to support benefit from statin use [2-5]. The most valuable data on the role of statin therapy in patients with systolic HF came from two large randomized trials published neither of which showed benefit.